The Uncertain Path Forward for Psychedelic Medicine

Quick Summary:

After the FDA rejected its proposed MDMA treatment, Lykos Therapeutics is laying off 75 percent of its staff and its founder has left the company.

In the Lykos trials, around 90 percent of the participants were able to correctly guess whether they received MDMA or a placebo, effectively “unblinding” the study.

Sandhya Prashad, president of the American Society of Ketamine Physicians, Psychotherapists, and Practitioners, says the therapy component likely complicated Lykos case to the FDA.“I don’t think the FDA knew what to do with that,” she says.

---

More Pictures

---

Read Quick SummarySave Time

or

Article Details

Author / Journalist: Emily Mullin

Category: TechnologyEconomy

Markets: United States

Topics: Science / Health Science

Source Website Secure: Yes (HTTPS)

News Sentiment: Neutral

Fact Checked: Legitimate

Article Type: News Report

Published On: 2024-08-15 @ 21:20:53 (13 hours ago)

News Timezone: GMT +8:00

News Source URL: wired.com

Language: English

Article Length: 1619 words

Reading Time: 9 minutes read

Sentences: 76 lines

Sentence Length: 22 words per sentence (average)

Platforms: Desktop Web, Mobile Web, iOS App, Android App

Copyright Owner: © Wired

News ID: 22089747

View Article Analysis

About Wired

Main Topics: TechnologyEconomy

Official Website: wired.com

Update Frequency: 16 posts per day

Year Established: 1993

Headquarters: United States

News Last Updated: 14 hours ago

Coverage Areas: United States

Ownership: Independent Company

Publication Timezone: GMT +8:00

Content Availability: Worldwide

News Language: English

RSS Feed: Available (XML)

API Access: Available (JSON, REST)

Website Security: Secure (HTTPS)

Publisher ID: #111

Publisher Details

Frequently Asked Questions